Merck & Co., Inc. Derivative Liability After Offset Subject To Master Netting Arrangement
Merck & Co., Inc. (MRK) had Derivative Liability After Offset Subject To Master Netting Arrangement of $41.00 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Offsetting › Derivative Liability, Subject to Master Netting Arrangement, after Offset and Deduction › Derivative Liability, Subject to Master Netting Arrangement, after Offset
us-gaap:DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement · last filed 2026-08-07
- 2026-06-30: Derivative Liability After Offset Subject To Master Netting Arrangement $41.00M.
- 2026-03-31: Derivative Liability After Offset Subject To Master Netting Arrangement $4.00M.
- 2025-12-31: Derivative Liability After Offset Subject To Master Netting Arrangement $79.00M.
- 2025-09-30: Derivative Liability After Offset Subject To Master Netting Arrangement $246.00M.
| Period end | Derivative Liability After Offset Subject To Master Netting Arrangement |
|---|---|
| 2026-06-30 | $41.00M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $79.00M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $246.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $313.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $29.00M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $46.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $73.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $28.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $56.00M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $24.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $38.00M 10-Q · filed 2023-11-03 |
| 2022-12-31 | $170.00M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |